Targeted Mevalonate Pathway and Autophagy in Antitumor Immunotherapy

What is it about?

Tumors of the digestive system are currently one of the leading causes of cancer-related death worldwide. Despite considerable progress in tumor immunotherapy, the prognosis for most patients remains poor. In the tumor microenvironment (TME), tumor cells attain immune escape through immune editing and acquire immune tolerance. The mevalonate pathway and autophagy play important roles in cancer biology, antitumor immunity, and regulation of the TME. In addition, there is metabolic crosstalk between the two pathways. However, their role in promoting immune tolerance in digestive system tumors has not previously been summarized. Therefore, this review focuses on the cancer biology of the mevalonate pathway and autophagy, the regulation of the TME, metabolic crosstalk between the pathways, and the evaluation of their efficacy as targeted inhibitors in clinical tumor immunotherapy.

Featured Image

Photo by Myriam Zilles on Unsplash

Photo by Myriam Zilles on Unsplash

Why is it important?

This review focuses on the cancer biology of the mevalonate pathway and autophagy, the regulation of the tumor microenvironment, metabolic crosstalk, and the evaluation of the efficacy of both targeted inhibitors in clinical tumor immunotherapy. We believe that our study makes a significant contribution to the literature because the mevalonate pathway and autophagy play important roles in cancer biology, antitumor immunity, and regulation of the tumor microenvironment. Here, we summarize their role in promoting immune tolerance in digestive system tumors both individually, and in combination. Further, we believe that this paper will be of interest to the readership of your journal because the combination of mevalonate metabolism and autophagy has considerable development prospects in antitumor therapy and may become a new strategy for antitumor clinical therapy in the future.

Perspectives